Novo Nordisk A/S
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Novo Nordisk A/S sits in the top decile of US sponsors by registered trial count (#81 of 15,742 sponsors by registered trial count).
Novo Nordisk A/S: 431 sponsored US clinical trials, 34 recruiting.
Novo Nordisk A/S sponsors 431 registered US clinical trials on ClinicalTrials.gov, 34 of them currently recruiting, and 342 completed. 243 of these trials are in Phase 3-4 (later-stage) and 155 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetes Mellitus, Type 2, with 48 trials.
Top-decile sponsor footprint
Novo Nordisk A/S ranks in the top decile of sponsors by registered trial count (#81 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
342 of 363 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
431 total, page 7 of 9
GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus
NCT01950637
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes
NCT01392573
Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects
NCT01473953
Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin
NCT01388361
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
NCT01401244
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
NCT01392547
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
NCT01272219
Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes
NCT01272232
Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus
NCT01364428
Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens
NCT01365507
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
NCT01336023
Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients
NCT01333111
A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors
NCT01830712
Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus
NCT01326026
Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency
NCT01253811
Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency
NCT01230021
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
NCT01232491
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
NCT01165684
Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
NCT01205724
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
NCT01179048
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
NCT01138501
Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)
NCT01135992
A Comparison Between Two Formulations of NN5401 in Healthy Subjects
NCT01125553
A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes
NCT01121276
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
NCT01076647
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
NCT01079234
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
NCT01068665
GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus
NCT01950650
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
NCT01068678
A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers
NCT01044108
Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin
NCT01046110
Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes
NCT01045447
The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin
NCT01043510
Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes
NCT01045707
Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes
NCT00943501
Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
NCT00984126
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
NCT00978380
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes
NCT00972283
Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes
NCT00982228
Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors
NCT00951405
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
NCT00982644
Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
NCT00978627
Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B
NCT00956345
Comparison of Two NN1250 Formulations in Healthy Volunteers
NCT00966368
Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery
NCT00914589
Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes
NCT00909480
PROPACT: Retrospective Prophylaxis Patient Case Collection
NCT00882778
Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects
NCT00840086
The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes
NCT00856986
Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir
NCT00873223
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 94 |
| Phase 2 | 61 |
| Phase 3 | 220 |
| Phase 4 | 23 |
Therapeutic Areas
Where Novo Nordisk A/S enrollment is open (later-stage tilt)
34 recruiting of 431 indexed (8% open); 342 completed (79%).
Phase mix: 243 late (III/IV) vs 155 early (I/II) (later-stage heavy).
Top condition: Diabetes Mellitus, Type 2 (48 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Novo Nordisk A/S: open-pipeline peers nationwide
Peers matched on 431 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Novo Nordisk A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 431 trials (± recruiting share)
- Children's Hospital of Philadelphia · 431 trials · 18% recruiting
- University of Illinois at Chicago · 430 trials · 27% recruiting
- Vanderbilt University · 430 trials · 3% recruiting
- Dartmouth-Hitchcock Medical Center · 427 trials · 12% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 8% recruiting · 305 trials
- Boston Scientific Corporation · 8% recruiting · 280 trials
- United Therapeutics · 8% recruiting · 63 trials
- Hoffmann-La Roche · 8% recruiting · 909 trials
Related
What to do with this Novo Nordisk A/S page
431 registered trials is a research-attention snapshot, not an endorsement of Novo Nordisk A/S or any single study.
- 34 of Novo Nordisk A/S's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Diabetes Mellitus, Type 2 is the condition Novo Nordisk A/S studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetes Mellitus, Type 2 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Novo Nordisk A/S pipeline card: 431 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.